Available online at www.sciencedirect.com
ScienceDirect
Bioorganic & Medicinal Chemistry 15 (2007) 3299–3300
Bioorganic & Medicinal Chemistry

Corrigendum

# Corrigendum to "Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors" [Bioorg. Med. Chem. 15 (2007) 1014–1021]

Xiaoxia Zheng,[a] Hiroyuki Oda,[a] Kayo Takamatsu,[a] Yukio Sugimoto,[a] Akihiro Tai,[a] Eiichi Akaho,[c] Hamed Ismail Ali,[c] Toshiyuki Oshiki,[b] Hiroki Kakuta[a,*] and Kenji Sasaki[a]

[a]*Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1, Tsushima-Naka, Okayama 700-8530, Japan*
[b]*Division of Chemistry and Biochemistry, Okayama University Graduate School of Natural Science and Technology, 3-1-1, Tsushima-Naka, Okayama 700-8530, Japan*
[c]*Faculty of Pharmaceutical Sciences, High Technology Research Center (Life Science Center), Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan*

Available online 12 February 2007

The following items should be corrected:

On page 1017, in Table 4, CI should be Cl.

On page 1018, in Table 6, **Si** should be **8i**, NH2 should be $NH_2$, and COX-1 $IC_{50}$ of compound **4**, which was shown to be 0.03, should be 0.1 μM.

On page 1019, in the legends to Figures 7, 8, and 9, 'versus vehicle' should be added after $^{**}p < 0.01$.

On page 1019, in Figure 8, the asterisks are missing.

The correct versions of the tables and figures are provided here.




**Figure 8.** Effect of COX inhibitors on carrageenan-induced edema. (a) Administered via po, (b) administered via ip. Single doses of vehicle (circle), 30 mg/kg **11f** (triangle), 30 mg/kg aspirin (square) or 10 mg/kg indomethacin (**4**) (open circle) were administered by oral gavage 1 h before initiation of inflammation with carrageenan. Edema was measured 4 h after carrageenan injection. Data shown are means ($n = 3$–8) ± SEM. $^{*}p < 0.05$, $^{**}p < 0.01$ versus vehicle.

DOI of original article: 10.1016/j.bmc.2006.10.029.
* Corresponding author. Tel.: +81 86 251 7977; fax: +81 86 251 7926; e-mail: kakuta@pharm.okayama-u.ac.jp

0968-0896/$ - see front matter 
doi:10.1016/j.bmc.2007.01.059

**Table 4.** COX-inhibitory activity of compounds **8** and **11**




| Compound | $NH_2$ | R | R' | % Inhibition of COX at 100 μM | |
|---|---|---|---|---|---|
| | | | | COX-1 | COX-2 |
| **4** | — | — | — | 90 | 90 |
| **8i** | *p* | H | 4-Cl | 70 | 50 |
| **8j** | *p* | H | 3-Cl | 18 | 16 |
| **8k** | *p* | H | 2-Cl | 53 | 8 |
| **8l** | *p* | H | 2,4-DiCl | 6 | 12 |
| **8m** | *p* | H | 4-F | 15 | 26 |
| **8n** | *p* | H | 4-Br | 23 | 25 |
| **8o** | *p* | H | 4-I | 18 | 50 |
| **11a** | *p* | Me | H | 48 | 16 |
| **11b** | *p* | Me | 4-Me | 21 | 16 |
| **11c** | *p* | Me | 4-OMe | 6 | 4 |
| **11d** | *p* | Me | 4-$CF_3$ | 9 | 6 |
| **11e** | *p* | Me | 4-F | 0 | 5 |
| **11f** | *p* | Me | 4-Cl | 78 | 29 |
| **11g** | *m* | Me | 4-Cl | 39 | 4 |
| **11h** | *p* | Et | 4-Cl | 10 | 19 |
| **11i** | *p* | Pr | 4-Cl | 0 | 5 |
| **11j** | *p* | Me | 4-Br | 21 | 8 |
| **11k** | *p* | Me | 4-I | 18 | 45 |

**Table 6.** COX-inhibitory activity of indomethacin (**4**), aspirin, and compounds **8i**, **11f**, and **15a**—**c**




| Compound | X | Y | R | R' | $IC_{50}$ (μM) | |
|---|---|---|---|---|---|---|
| | | | | | COX-1 | COX-2 |
| **8i** | Cl | $NH_2$ | H | H | 12.0 | >100 |
| **11f** | Cl | $NH_2$ | H | Me | 3.2 | >100 |
| **15a** | $NH_2$ | Cl | H | Me | 9.2 | >100 |
| **15b** | $NH_2$ | Cl | Me | Me | 26.0 | >100 |
| **15c** | $NH_2$ | Cl | OMe | Me | 20.0 | >100 |
| **Aspirin** | | | | | 100 | >100 |
| **4** | | | | | 0.1 | 7.7 |